Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products

Products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DC70865 UHRF1 PHD inhibitor MLD4 Featured
UHRF1 PHD inhibitor MLD4 is a specific compound that selectively inhibits the UHRF1-histone interaction (IC50=12.4 uM), targets the PHD finger of UHRF1, specifically disrupting histone H3 arginine 2 interactions with the PHD finger.UHRF1 PHD inhibitor MLD4 inhibited binding between H3K9me3(FAM) and UHRF1 with IC50 of 24-26 uM, displace UHRF1-histone H3 binding in cells.
More description
DC70653 NJH-2-075 Featured
NJH-2-075 is an alkyne-functionalized probe of EN523, retains binding to OTUB1 in vitro.
More description
DC70866 UHRF1 PHD inhibitor MLD5
UHRF1 PHD inhibitor MLD5 is a specific compound that selectively inhibits the UHRF1-histone interaction (IC50=7.4 uM), targets the PHD finger of UHRF1, specifically disrupting histone H3 arginine 2 interactions with the PHD finger.UHRF1 PHD inhibitor MLD5 inhibited binding between H3K9me3(FAM) and UHRF1 with IC50 of 24-26 uM, displace UHRF1-histone H3 binding in cells.
More description
DC65027 9H-Purin-6-amine, 2-chloro-N-[(4,6-dimethyl-3-pyridinyl)methyl]-9-(1-methylethyl)- Featured
DC65149 CPD3236 Featured
DC65059 5-Methylsulfonyl-2-(2,2,2-trifluoro-1-Methylethoxy)benzoic acid Featured
DC60454 BRD-K56819078 Featured
BRD-K56819078 is a small-molecule senolytics and significantly decreases senescent cell burden and mRNA expression of senescence-associated genes in the kidneys of aged mices.
More description
DC60456 HHS-166 Featured
HHS-166 shows dose-dependent inhibition of arsenite-induced stress granule (SG) formation, and liganded G3BP1 Y40 in the NTF2 dimerization domain of this essential nucleating protein for SG regulation.
More description
DC60457 AHL-030 Featured
AHL-030 is a potent and selective EDC3-targeted ligands. AHL-030 is also an stress granules (SGs) enhancer and results in a 2-fold increase in SGs per arsenite-treated cell.
More description
DC65238 compound 53 Featured
”Compound 53” (University of Texas Southwestern Medical Center) is a stimulator of interferon (IFN) genes (STING) agonist.
More description
DC65240 Compound 4e Featured
“compound 4e” (Chiesi Farmaceutici) is an inhaled p38α/β mitogen-activated protein kinase (MAPK) inhibitor being developed for lung inflammatory diseases.
More description
DC65256 compound 6 Featured
“Compound 6” (Novartis) is a first-in-class YAP-TEAD protein-protein inhibitor. The TEAD transcription factor and its coactivator YAP and WWTR1/TAZ of the Hippo pathway are responsible for directly regulating the expression of genes involved in cell proliferation and organ size.
More description
DC65257 compound 29 Featured
Overcoming FGFR mutation resistance and FGFR1-mediated hyperphosphatemia toxicity through isoform-selective FGFR2/3 inhibition. “Compound 29” is an ATP-competitive fibroblast growth factor receptor (FGFR) 2/3 inhibitor with subnanomolar potency.
More description
DC65252 compound 27 Featured
compound 27, is a potent (13 nM) CNS-penetrant compound that reduces very long chain fatty acid (VLCFA) levels in the CNS, which are believed to be pathological in the rare disease adrenoleukodystrophy (ALD). The starting point came from an HTS on compounds from an internal collection.
More description
DC65253 compound 14d Featured
“Compound 14d” (Shionogi & Co.) is a highly potent, dose-dependent adenosine monophosphate activated protein kinase (AMPK) activator being investigated for its blood-glucose-lowering effects.
More description
DC65266 GLS-409
DC65270 DKR-1677 Featured
DC20649 AKB-9778 Featured
AKB-9778 is a potent, selective inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP) with IC50 of 17 pM.
More description
DC65273 Compound 16 Featured
DC65275 PFKFB3inhibitor(Compound69) Featured
DC65279 NPD2381 Featured
DC20257 KMN-159 Featured
KMN-159 is a potent prostaglandin E2 type 4 (EP4) receptor agonist with Ki of 0.38 nM and shows five fold increase in potency versus KMN-80.
More description
DC26194 VU6003586 Featured
VU6003586 is a novel allosteric modulators of mGlu5 with EC50 of 174 nM.
More description
DC26190 DS54360155 Featured
DS54360155 is an orally potent analgesic without μ-opioid receptor agonist activity.
More description
DC28065 UCSF7447 Featured
UCSF7447 is a selective and inverse agonists of melatonin receptor 1 (MT1) with EC50 of 41 nM, and shows 53-fold selectivity for human MT1 over human MT2.
More description
DC28064 UCSF3384 Featured
UCSF3384 is a selective and inverse agonists of melatonin receptor 1 (MT1) with EC50 of 21 nM, and shows 31-fold selectivity for human MT1 over human MT2.
More description
DC28066 UCSF4226 Featured
UCSF4226 is a selective and inverse agonists of melatonin receptor 1 (MT2) with EC50 of 6.3 nM, and shows 91-fold selectivity for human MT2 over human MT1.
More description
DC53048 HST5040 Featured
HST5040 is a clinical candidate for the treatment of propionic acidemia (PA) and methylmalonic acidemia (MMA) with EC50 of 0.94 μM in P-CoA-lowering activity.
More description
DC65341 [18F]PSMA-1007 Featured
[18F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of biochemical recurrence, which significantly affects patient management. Herein, we established and optimized a one-step radiolabeling protocol to separate and purify [18F]PSMA-1007 with a CFN-MPS200 synthesizer for clinical application.
More description
DC60481 SC9 Featured
SC9 is an uncompetitive inhibitor of WT dynamin-related protein 1 (Drp1) with IC50 of 270 nM. SC9 completely prevents the LPS-induced decline in cells with fused mitochondria.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X